Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

DSpace/Manakin Repository

Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

dc.contributor.author	Tefferi, A
dc.contributor.author	Abdel-Wahab, O
dc.contributor.author	Cervantes, F
dc.contributor.author	Crispino, J D
dc.contributor.author	Finazzi, G
dc.contributor.author	Girodon, F
dc.contributor.author	Gisslinger, H
dc.contributor.author	Gotlib, J
dc.contributor.author	Kiladjian, J-J
dc.contributor.author	Licht, J D
dc.contributor.author	Odenike, O
dc.contributor.author	Pardanani, A
dc.contributor.author	Silver, R T
dc.contributor.author	Solary, E
dc.contributor.author	Mughal, T
dc.contributor.author	Mullally, Ann
dc.contributor.author	Levine, R L
dc.date.accessioned	2012-04-19T19:27:17Z
dc.date.issued	2011
dc.identifier.citation	Tefferi, A.O., Abdel-Wahab, F. Cervantes, J.D. Crispino, G. Finazzi, F. Girodon, H. Gisslinger, et al. 2011. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: proceedings from the 5th international post-ash symposium. Blood Cancer Journal 1(3): e7.	en_US
dc.identifier.issn	2044-5385	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8603493
dc.description.abstract	Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7–8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-α, midostaurin and cladribine. In addition, the new ‘Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Nature Publishing Group	en_US
dc.relation.isversionof	doi:10.1038/bcj.2011.4	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255279/pdf/	en_US
dash.license	LAA
dc.subject	myeloproliferative	en_US
dc.subject	myelofibrosis	en_US
dc.subject	polycythemia	en_US
dc.subject	thrombocythemia	en_US
dc.subject	mastocytosis	en_US
dc.title	Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Blood Cancer Journal	en_US
dash.depositing.author	Mullally, Ann
dc.date.available	2012-04-19T19:27:17Z